Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
Ημερομηνία
2012Συγγραφέας
Skarlos, P.Christodoulou, C.
Kalogeras, K. T.
Eleftheraki, A. G.
Bobos, M.
Batistatou, Anna
Valavanis, C.
Tzaida, O.
Timotheadou, E.
Kronenwett, R.
Wirtz, R. M.
Kostopoulos, I.
Televantou, D.
Koutselini, E.
Papaspirou, I.
Papadimitriou, C.
Pectasides, Dimitrios
Gogas, H.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Arapantoni, P.
Skarlos, Dimosthenis V.
Fountzilas, George
Source
Cancer chemotherapy and pharmacologyVolume
69Issue
2Pages
533-546Google Scholar check
Keyword(s):
Metadata
Εμφάνιση πλήρους εγγραφήςΕπιτομή
Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate the outcome of the respective groups of patients and specifically of those with triple-negative breast cancer (TNBC) following dose-dense sequential adjuvant chemotherapy. Methods: A total of 595 patients with high-risk breast cancer were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy with or without paclitaxel in the context of a randomized study. ER, PgR, HER2, Ki67, EGFR, and CK5 protein expression were evaluated in 298 formalin-fixed paraffin-embedded tumor samples by immunohistochemistry (IHC). HER2 was also evaluated by chromogen in situ hybridization (CISH). HER2 status and Ki67 protein expression differentiated luminal IHC subtypes (luminal B tumors being HER2 and/or Ki67-positive). Results: Among the 298 tumors, the immunohistochemical panel classified 37 (12%) as luminal A, 198 (66%) as luminal B, 27 (9%) as HER2 enriched, and 36 (12%) as TNBC. The median follow-up time was 97 months. Patients with luminal A tumors had the best prognosis, with improved disease-free survival (log-rank, P = 0.033) and overall survival (P = 0.006) compared with the other three tumor subtypes. The three subtypes had an increased risk for relapse and death compared with luminal A in multivariate analysis, as well. No benefit from paclitaxel treatment was detected in any of the four subtypes or the total cohort. Hierarchical clustering based on mRNA expression of ER, PgR, and HER2 by quantitative RT-PCR identified patient groups that were comparable to the subtypes identified by IHC. Conclusions: The results of this study confirm that triple negative, luminal B and HER2-enriched phenotypes identified by IHC are of adverse prognostic value in high-risk breast cancer patients treated with dose-dense sequential adjuvant chemotherapy. © 2011 Springer-Verlag.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety
Pentheroudakis, George; Razi, E. D.; Athanasiades, A.; Pavlidis, Nicholas; Fountzilas, George (2006)Patients with metastatic breast cancer receive multiple lines of cytotoxic chemotherapy, with taxane and anthracycline-based regimens being the most active. Anthracyclines carry the risk of significant cardiotoxicity at ...
-
Article
Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)
Pentheroudakis, George; Kotoula, V.; Eleftheraki, A. G.; Tsolaki, E.; Wirtz, R. M.; Kalogeras, K. T.; Batistatou, Anna; Bobos, M.; Dimopoulos, M. A.; Timotheadou, E.; Gogas, H.; Christodoulou, C.; Papadopoulou, K.; Efstratiou, I.; Scopa, C. D.; Papaspirou, I.; Vlachodimitropoulos, D.; Linardou, H.; Samantas, E.; Pectasides, Dimitrios; Pavlidis, Nicholas; Fountzilas, George (2013)Background:Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer.Patients and Methods:Formalin-fixed paraffin-embedded tumor blocks were collected ...
-
Article
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: Parallel topotecan escalation in two fixed platinum dosing schemes
Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Mauri, D.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2005)Purpose: We performed a phase I study of two fixed dosing schemes of cisplatin, a DNA cross-linker, with intravenous escalating topotecan, a DNA-topoisomerase I inhibitor. Experimental Design: 40 patients with advanced ...